INTERNATIONAL JOURNAL IN PHARMACEUTICAL SCIENCES

Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Revolutionizing Therapeutics: A Comprehensive Review On Clinical Approach Innovations In Drug Delivery Systems

Varshini Y*, Satish S

Department of pharmacy practice, Srinivas College of Pharmacy, Mangalore, 574143

ARTICLE INFO

Received: 14 Dec 2023
Accepted: 18 Dec 2023
Published: 23 Dec 2023

Keywords:
patches, skin, transdermal system drug delivery, permeation, medication, novel drug delivery system

DOI:
10.5281/zenodo.10423901

ABSTRACT

The skin offers an accessible & convenient site for the administration of medication. The transdermal drug delivery system has been a safe &effective drug delivery system, it aims to deliver the drug through the skin at a predetermined rate and controlled rate. If a drug has the right mix of physical chemistry and pharmacology, transdermal delivery is a remarkably effective route of administration. The transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose & medication through the skin & into the bloodstream. Often, this promotes healing to an injured area of the body. An advantage of the TDDS route over other types of medication delivery such as oral, topical, and IV is that the patch provides a controlled release of medication into the patient. Due to the large advantages of TDDS, many new researches are going on today to incorporate newer drugs via this system.

INTRODUCTION

Drug delivery systems play a crucial role in enhancing therapeutic efficacy by ensuring the optimal delivery of medications to the target tissue at the appropriate time and in the appropriate amount, while minimizing toxicity and adverse effects [1]. Traditional drug delivery systems have limitations such as low bioavailability and inability to produce continuous release, which can render the therapeutic process ineffective [2]. The development of nanotechnology and nano-drug delivery carriers has revolutionized the biomedical industry, enabling improved aqueous dispersibility, stability, and cell-specific targeting of drugs [3]. Nano-drug delivery systems have shown promising results in improving the accuracy and efficacy of drug delivery [4]. Additionally, the advent of stimuli-responsive controlled drug release systems has further enhanced therapeutic outcomes by achieving precise control over drug release in response to specific stimuli [5]. Overall, drug delivery systems, especially nano-drug delivery systems and stimuli-responsive controlled drug release systems, have the potential to significantly

***Corresponding Author:** Varshini Y
Address: *Department of pharmacy practice, Srinivas College of Pharmacy, Mangalore, 574143*
Email : varshinimahadi@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

enhance therapeutic efficacy and improve patient outcomes.

Clinical applications:

In the realm of drug delivery systems, the clinical application of innovative approaches has the potential to revolutionize patient care. From nanoparticles to liposomes and targeted delivery technologies, the integration of these advancements into clinical practice holds great promise. Nanoparticles, with their ability to enhance drug bioavailability and target specific cells, are paving the way for more effective and less toxic treatments. Liposomes, as versatile carriers, exhibit tremendous potential in the controlled release of therapeutic agents, particularly in cancer management. Targeted delivery technologies, utilizing ligands or antibodies, allow for precise localization of drugs, minimizing off-target effects. These innovations not only offer solutions to existing challenges, such as poor drug solubility and side effects but also open new avenues for personalized and tailored therapeutic interventions. As these technologies progress from the laboratory to clinical trials, their successful application holds the key to optimizing treatment outcomes, minimizing adverse effects, and ultimately transforming the landscape of patient-centered healthcare.

Exploring Conventional Paths: Limitations in Traditional Drug Delivery Methods:

Traditional drug delivery methods have limitations in terms of drug efficacy, side effects, and control over drug release. These limitations have led to the development of novel drug delivery systems (NDDS) that address these issues [6] [7]. Traditional transdermal drug delivery, for example, has the advantages of rapid onset of activity and low side effects, but is not suitable for hydrophilic drugs and bioactive substances [8]. Conventional drug delivery systems also face challenges in achieving controlled drug delivery at the desired rate and time. Micro electro-mechanical systems (MEMS) technology, such as lab on chip (LOC) and point-of-care devices, offer solutions for controlled drug delivery and implantable devices with minimal side effects [9]. The development of NDDS and implantable drug delivery systems (IDDS) allows for controlled drug release in a low concentration and follows a zero-order release pattern . Pharmaceutical companies are actively working on developing novel drug delivery systems to improve drug administration and reduce side effects .

PRECISION MEDICINE,

also known as personalized medicine, is an innovative approach to healthcare that tailor's medical treatment and interventions to the individual characteristics of each patient. This transformative model takes into account an individual's unique genetic makeup, lifestyle, environment, and specific health conditions to design personalized therapeutic strategies. Advances in genomic research and technology have played a pivotal role in the development of precision medicine by enabling the identification of genetic variations associated with disease susceptibility, progression, and response to treatment. By understanding the molecular and genetic underpinnings of diseases, healthcare providers can make more informed decisions about treatment options, selecting therapies that are not only effective but also have fewer adverse effects. Precision medicine has the potential to revolutionize healthcare, offering more targeted and efficient treatments, improving patient outcomes, and paving the way for a new era of personalized and precise medical interventions.

NEED OF INNOVATIVE PARADIGMS IN DRUG DELIVERY:

Novel approaches and techniques in drug delivery include ocular drug delivery methods for retinal diseases, such as sustained-release implants, depots, and gene therapy [10]. Transdermal drug

delivery systems (TDDS) mediated by microneedles have shown promise for delivering proteinaceous drugs [11]. Gallic acid as a nanocarrier has potential for treating disorders caused by oxidative damage, and nanotechnology can enhance its therapeutic potential [12]. Herbal medicines can be delivered using innovative drug delivery systems like phytosomes, ethosomes, and nanoparticles, which improve effectiveness and safety [13]. Ethosomes, soft vesicular carriers containing ethanol, have emerged as a novel approach for transdermal drug delivery, offering improved efficacy and non-invasive delivery of various agents [14].

Nanoparticles as Drug Delivery Systems: A Clinical Approach

Nanoparticles have emerged as promising candidates for drug delivery systems, revolutionizing the landscape of clinical therapeutics. Their unique properties, such as small size, large surface area, and tunable surface chemistry, allow for precise control over drug release kinetics and distribution within the body. One compelling application of nanoparticle-based drug delivery is in the management of chronic diseases, exemplified by their role in cancer treatment. Nanoparticles can enhance the bioavailability of anticancer drugs, improve their solubility, and enable targeted delivery to tumor sites, thereby minimizing damage to healthy tissues. Additionally, the versatility of nanoparticles extends to various therapeutic modalities, including gene therapy and immunotherapy. This clinical approach harnesses the potential of nanoparticles to encapsulate and deliver therapeutic payloads directly to specific cells or tissues, optimizing drug efficacy while mitigating side effects. As ongoing research continues to unveil the full scope of nanoparticle applications, the clinical integration of these advanced drug delivery systems promises to redefine disease management strategies and elevate the precision and effectiveness of therapeutic interventions15-19.

TYPES:

Polymeric and lipid-based nanoparticles are types of nanoparticles used in drug delivery. These nanoparticles have shown promise in enhancing drug delivery to the brain for the treatment of neuropsychiatric disorders and neurological diseases [20]. Lipid-based nanoparticles, specifically lipid-based polymeric nanoparticles, have been used for the delivery of RNA molecules in RNA therapy [21]. Polymeric nanoparticles have also been explored as drug delivery systems for improving the bioavailability of drugs, delivering drugs to specific sites, and enhancing solubility of drugs [22]. In the field of cancer treatment, polymeric nanoparticles have been developed as nanocarriers for delivering anti-cancer therapeutics, with a focus on their synthesis and drug delivery applications [23]. Additionally, solid lipid nanoparticles have been used as carriers for delivering poorly water-soluble drugs, with the potential for sustained drug release and targeted delivery [24].

ADVANTAGES:

Nanoparticles offer several advantages in drug delivery, including improved drug delivery and enhanced cellular uptake. These nanocarriers can deliver drugs more precisely to specific organs, improving their pharmacokinetics and avoiding adverse effects on non-target tissues [25]. Different types of nanovectors, such as liposomes, dendrimers, and nanoparticles, have been studied for their potential in cancer therapy and diagnostics [26]. Nanofibers have also emerged as novel nanomaterials that provide enhanced bioavailability, targeted drug release, and reduced toxicity [27]. In the case of mesalazine, a drug used to treat inflammatory bowel diseases, the use of a poly(amidoamine) (PAMAM) dendrimer as a carrier has shown to increase the bioavailability of the drug, enhance cellular uptake, and improve its

anti-inflammatory activity [28] [29]. Additionally, thermally sensitive liposomes have been developed to release drugs inside tumor vasculature, increasing drug bioavailability and penetration into tumorcells . Overall, nanoparticles have the potential to significantly improve drug delivery and enhance cellular uptake in various therapeutic applications.

INNOVATIONS

Recent developments in the field of drug delivery systems have focused on the use of nanoparticles. Nanomaterials, such as solid lipid nanoparticles (SLNs) [30], have shown great potential in various applications including drug delivery, clinical treatment, and research. Nanoparticle drug delivery systems have been found to have anti-tumor effects and can be used to target specific sites [31]. Additionally, nanocarriers, such as lipid-based nanocarriers and polymer nanocarriers, have been developed for co-delivery of therapeutic agents, including nucleic acids and chemotherapeutic drugs [32]. These combined drug delivery approaches have shown synergistic therapeutic effects and can overcome multidrug resistance in cancer cells [33]. The use of nanoparticles in ophthalmic formulations has also been explored to improve drug release and enhance drug penetration across ocular tissues [34]. Overall, recent developments in nanoparticle-based drug delivery systems have shown promise in improving drug delivery efficiency and therapeutic efficacy.

Liposomes as Implantable Drug Delivery Systems:

A Clinical Approach:

Implantable drug delivery systems, particularly those utilizing liposomes, have garnered significant attention in clinical settings due to their potential to revolutionize treatment approaches. Liposomes, lipid-based vesicles, serve as versatile carriers for various therapeutic agents, offering unique advantages for controlled and sustained drug release. In clinical applications, implantable liposomal drug delivery systems have proven effective in managing chronic conditions, such as pain management and cancer therapy. The encapsulation of drugs within liposomes not only enhances drug stability but also allows for targeted delivery to specific tissues or organs, reducing systemic side effects. The controlled release kinetics offered by liposomal implants offer prolonged therapeutic effects, minimizing the need for frequent administrations. Additionally, liposomal formulations provide a platform for customized drug release profiles, tailoring treatment strategies to individual patient needs. As clinical research continues to unfold, the integration of liposomes as implantable drug delivery systems holds great promise in optimizing therapeutic outcomes, improving patient compliance, and advancing the precision of clinical interventions 35-39.

Implant Innovations: Exploring Diverse Types for Advanced Drug Delivery.

Implants used in drug delivery encompass a diverse array of devices designed to provide controlled and sustained release of therapeutic agents within the body. One common type of implant is the polymeric matrix system, where drugs are encapsulated within biocompatible polymers that gradually degrade over time, releasing the drug payload. For instance, biodegradable polymer implants, such as those made from polylactic acid (PLA) or polyglycolic acid (PGA), have been employed for the controlled release of hormones, contraceptives, and anti-inflammatory drugs. Another notable category is the reservoir system, where drugs are stored in a reservoir within the implant, often covered by a semipermeable membrane. This design allows for a more precise control of drug release rates. Examples include subcutaneous implants like Norplant, which provides a long-acting contraceptive effect. Furthermore, osmotic pumps

represent a distinct class, relying on osmotic pressure to release drugs at a controlled rate. These pumps are often used for the delivery of cardiovascular drugs and pain management medications. The variety of implantable drug delivery systems underscores their versatility in addressing different medical needs while offering the advantages of prolonged therapeutic effects and enhanced patient compliance 40-44.

Liposomes on the Cutting Edge: Recent Advances in Drug Delivery Systems

Recent advances in liposomes-based drug delivery systems have led to significant progress in the field of innovative active biomolecule drug delivery systems. Liposomes, which are safe and biocompatible nanosized vesicles, have been widely used for systemic and brain delivery, as well as for vaccine delivery. They can protect drugs and genes from degradation, enhance drug absorption, and prolong residence time in the nasal cavity [45]. Liposomes have also been extensively studied as ideal platforms for the delivery of nucleic acid therapeutics, with a focus on cancer therapeutics. The advancements in liposomes' nano-formulations, functionalization, and design have greatly contributed to the field of nucleic acid therapy [46]. Additionally, liposomes have been used in targeted drug delivery systems, which aim to deliver therapeutics to specific target sites while minimizing exposure to non-target sites [47]. Overall, liposomes-based drug delivery systems have shown great potential in improving drug delivery, with applications in various diseases and organs of the body [48].

IMPLANTS AS DRUG DELIVERY SYSTEM:

Implantable drug delivery systems are novel drug delivery systems that provide controlled release of drugs for extended periods of time. These systems offer advantages such as targeted distribution, constant release rate, and reduced adverse effects, making them safer and more effective than traditional routes of drug administration [49] [50]. They are particularly useful for conditions that require long-term medication or face issues with patient compliance, such as cardiovascular disease, TB, diabetes, cancer, and chronic pain [51]. Implantable drug delivery systems can be made from a variety of materials, both nondegradable and biodegradable, depending on the drug being delivered and the desired release duration [52]. There are different implantable technologies currently in use for various therapeutic applications, including dentistry, ophthalmology, contraception, and oncology [53]. However, the high cost and the need for further enhancement and scientific trials before widespread implementation are challenges that need to be addressed . The future prospects of implantable drug delivery systems lie in precision and customized medicine .

TYPES:

Implants used in drug delivery include miniaturized neural implants for precise and controllable drug delivery in the brain [54]. Titanium and its alloys are also used to fabricate orthopaedic and dental implants for localized drug delivery [55]. Polymeric drug delivery systems implanted in the body provide prolonged and controlled release of drugs [56]. Surface modifications of titanium-based implants, such as electrochemically anodized titania nanotubes (TNTs), enable local drug release. Fused deposition molding (FDM) is another technique used to prepare drug delivery implants with personalized administration [57]. These implants can be fabricated using drug-loaded filaments developed through hot-melt extrusion (HME) and can achieve controlled and efficient drug release.

INNOVATIONS AND CHALLENGES

Implantable drug delivery systems offer several advantages such as targeted distribution, constant release rate, and reduced adverse effects, making them safer and more effective than traditional routes of drug administration [58]. These systems

allow for the optimisation of therapeutic properties of drugs and can be used for various therapeutic applications [59]. However, the high cost of these systems and the need for further enhancement and scientific trials before wide implementation hinder their large-scale use [60]. In the field of drug delivery systems, the real challenge lies in achieving controlled drug delivery at the desired rate and time [61]. Micro electro-mechanical systems (MEMS) technology provides a solution by enabling precise control of drug delivery parameters and minimising side effects [62]. Implantable drug delivery systems have the potential to sustain therapeutic medication doses for long durations, making them useful for conditions that require long-term medication or face issues with patient compliance . However, successful drug delivery in the musculoskeletal system (MSKS) poses challenges due to the abundance of extracellular matrix and differences in vascularity among various MSKS tissues . Controlled drug delivery systems, including nano-drug delivery and targeted delivery using intelligent biomaterials, have evolved to overcome the limitations of conventional drug delivery systems.

INNOVATIONS AND APPLICATIONS:

Implantable drug delivery systems have seen recent advancements and applications in the field of medicine. These systems offer controlled drug release, targeted distribution, and location specificity, resulting in improved efficacy and reduced adverse effects [63]. One such advancement is the use of micro electro-mechanical systems (MEMS) technology, which allows for precise control of drug delivery parameters and miniaturization of devices [64]. Implantable drug delivery systems have been found to be particularly useful in the management of various diseases, including cardiovascular disease, TB, diabetes, cancer, and chronic pain, where long-term medication or patient compliance is a challenge [65]. However, the high cost and the need for further enhancement and scientific trials before wide implementation hinder their large-scale use [66]. Despite these limitations, implantable drug delivery systems hold promise for the future of precision and customized medicine [67].

RATIONALE FOR TARGETED DRUG DELIVERY:

Targeted drug delivery is a promising approach in medicine that aims to deliver drugs directly to the desired site, reducing side effects and improving therapeutic efficacy [68] - [71]. It involves the use of carrier systems such as nanoparticles, liposomes, and monoclonal antibodies to deliver drugs to specific tissues or cells [72]. Targeted drug delivery offers advantages in various disease indications, including oncology, cardiovascular diseases, neurological diseases, and respiratory diseases . However, there are challenges in scaling up and translating preclinical research to clinical success, as well as obtaining regulatory approval . Despite these challenges, targeted drug delivery holds great potential for personalized medicine and improving patient outcomes.

TARGETING STRATEGIES:

Passive and active targeting are two strategies used in drug delivery systems. Passive targeting takes advantage of the physiological conditions of the body to deliver drugs to the target site. This strategy utilizes the leaky vasculature of tumor blood vessels to passively deliver drugs to the tumorsite . On the other hand, active targeting involves the use of ligands to mediate drug delivery. Ligands bind to overexpressed receptors on tumor cells, allowing for specific targeting [73]. Active targeting can be achieved by attaching bio-recognition molecules to the surface of nanoparticles, which target specific markers overexpressed by cancer cells [74]. These targeting strategies aim to enhance the selective uptake of drugs into tumor cells, improving

therapeutic efficacy and reducing adverse effects on healthy tissues [75] [76].

INNOVATIONS IN TARGETED DDS

Recent developments in targeted drug delivery systems (DDS) have focused on the use of peptide ligands for cancer cell-surface receptors [77]. Peptides with high binding affinities to receptors overexpressed in cancer cells have been utilized for the delivery of anticancer drugs, genes, siRNAs, and molecular imaging agents using nanoparticles [78]. Peptide-modified PEGylated liposome-encapsulated drugs have shown effectiveness in cancer-targeted therapy and imaging [79]. Additionally, efforts have been made to improve binding affinity and endosomal escape using spacer peptides and stimuli [80]. In the field of neurodegenerative diseases, small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) have been developed as potential therapeutics for Parkinson's disease [81]. These inhibitors target the kinase activity of LRRK2, which is pathogenically linked to Parkinson's disease. The development of highly selective and potent LRRK2 inhibitors has shown promise in preclinical testing. Overall, these advancements in targeted DDS offer potential solutions for cancer treatment and neurodegenerative diseases like Parkinson's

Prospects:

Safety and regulatory considerations are paramount in the development and deployment of novel drug delivery systems. As these advanced technologies, including nanoparticles, liposomes, implants, and targeted delivery systems, continue to evolve, ensuring their safety profile and adherence to regulatory standards becomes imperative. Rigorous preclinical studies are essential to comprehensively evaluate potential toxicities, biocompatibility, and long-term effects on biological systems. Additionally, navigating the regulatory landscape requires meticulous attention to guidelines established by health authorities to guarantee the efficacy, quality, and safety of these innovative drug delivery systems.

Close collaboration between researchers, industry stakeholders, and regulatory bodies is crucial to establish robust frameworks for evaluating and approving these novel approaches. Striking the right balance between innovation and safety will not only expedite the translation of groundbreaking technologies into clinical applications but also instill confidence in healthcare professionals and the wider public regarding the reliability and safety of these novel drug delivery systems 82-83.

Transcendence:

Overcoming challenges in drug delivery represents a pivotal frontier in pharmaceutical research. Traditional drug delivery methods often face limitations such as poor bioavailability, lack of specificity, and the potential for systemic side effects. However, recent advancements in nanotechnology, biomaterials, and targeted delivery strategies are paving the way for innovative solutions. Nanoparticle-based drug carriers, for example, offer enhanced drug stability, improved solubility, and the ability to precisely target specific cells or tissues. Biomaterials play a crucial role in designing delivery systems that are biocompatible, allowing for sustained release and minimizing immune responses. Targeted delivery approaches, utilizing ligands or antibodies, enable the selective delivery of drugs to specific sites, maximizing therapeutic impact while minimizing off-target effects. As researchers continue to unravel the complexities of drug delivery challenges, these breakthroughs hold promise in revolutionizing treatment outcomes and fostering a new era of more effective and patient-friendly therapeutic interventions.

CONCLUSION

In conclusion, this comprehensive review has highlighted the transformative landscape of drug delivery systems, showcasing the remarkable

innovations in nanoparticles, liposomes, implants, and targeted delivery technologies. The integration of these cutting-edge approaches has ushered in a new era in therapeutics, offering unprecedented precision and efficacy. Nanoparticles have demonstrated their versatility in enhancing drug bioavailability, while liposomes provide a sophisticated platform for controlled release. Implants offer sustained therapeutic effects, and targeted delivery technologies promise to revolutionize treatment strategies. The synergistic combination of these advancements holds immense potential for personalized medicine, optimizing outcomes and minimizing adverse effects. As we look to the future, the continued exploration of these innovative drug delivery systems will undoubtedly shape the next generation of therapeutics, providing tailored solutions for diverse medical challenges and further advancing the frontiers of patient-centered care.

REFERENCES

1. Gomase V.S, LI S.-G., Vijaya Lakshmi A, et al. Drug delivery system: A novel approach to formulation development. International Journal of Pharmaceutical Sciences Review and Research. 2023;79(2). doi:10.47583/ijpsrr.2023.v79i02.035
2. Retnakumari AP, Anto RJ. Application of nano-drug delivery systems in improving the therapeutic efficacy of bioactive natural products. Advanced Pharmaceutical and Herbal Nanoscience for Targeted Drug Delivery Systems Part I. 2022;104–32. doi:10.2174/9789815036510122010008
3. Shukla SS, Pandey RK, Kalyani G. Controlled Drug Delivery Systems. Advancements in Controlled Drug Delivery Systems. 2022;184–204. doi:10.4018/978-1-7998-8908-3.ch008
4. Alkufi H, Salman A, Taher S. Principles and advantages of New Drug Delivery Technologie. Journal of Complementary Medicine Research. 2023;14(3):6. doi:10.5455/jcmr.2023.14.03.02
5. Das BC, Chokkalingam P, Masilamani P, Shukla S, Das S. Stimuli-responsive boron-based materials in drug delivery. International Journal of Molecular Sciences. 2023;24(3):2757. doi:10.3390/ijms24032757
6. Swati Kale, PratibhaSonawane, Shweta Mantri, ShubhangiThopate, Allabaksha Shaikh. An overview: Novel herbal drug delivery system. International Journal For Multidisciplinary Research. 2023;5(1). doi:10.36948/ijfmr.2023.v05i01.1449
7. Li H, Li J, Xu J, Li L, Wang Y, Liu C, et al. Advances in dermatological application of Gelma Hydrogel Microneedles. Skin Research and Technology. 2023;29(4). doi:10.1111/srt.13327
8. AJMAL DrG. Implantable Drug Delivery Systems. NOVEL DRUG DELIVERY SYSTEM. 2022; doi:10.52458/9789391842871.2022.eb.grf.asu.ch.17
9. Jain SK, Sahu A, Keservani RK. Oral Drug Delivery System. Advances in Novel Formulations for Drug Delivery. 2023;383–400. doi:10.1002/9781394167708.ch21
10. Ham Y, Mehta H, Kang-Mieler J, Mieler WF, Chang A. Novel drug delivery methods and approaches for the treatment of retinal diseases. Asia-Pacific Journal of Ophthalmology. 2023;12(4):402–13. doi:10.1097/apo.0000000000000623
11. Chakraborty R, Afrose N, Kuotsu K. Novel synergistic approaches of protein delivery through physical enhancement for Transdermal Microneedle Drug Delivery: A Review. Journal of Drug Delivery Science and Technology. 2023;84:104467. doi:10.1016/j.jddst.2023.104467

12. V S, Deepika A, Jain PS, Swetha B, Evangilin PT. Novel drug delivery system and characterization in advance techniques. IP International Journal of Comprehensive and Advanced Pharmacology. 2023;8(1):36–41. doi:10.18231/j.ijcaap.2023.006
13. Kashid Poonam Nanaso, Prof.Shubhda. S. Pawar. Approaches in novel herbal drug delivery system. International Journal of Advanced Research in Science, Communication and Technology. 2023;568–77. doi:10.48175/ijarsct-7917
14. Devaki J, Pavuluri S, Suma N. Ethosomes: A vesicular carrier as a novel tool for Transdermal Drug Delivery System. Journal of Drug Delivery and Therapeutics. 2023;13(4):159–64. doi:10.22270/jddt.v13i4.5796
15. Rehman N, Pandey A. Future of nanomedicine and Drug Delivery System. Engineered Nanoparticles as Drug Delivery Systems. 2022;101–4. doi:10.1201/9781003252122-10
16. KannadasanDrM, Bichala PK, Agrawal A, Singh S. A review: Nano Particle Drug Delivery System. International Journal of Pharmaceutical Sciences and Medicine. 2020;5(12):46–58. doi:10.47760/ijpsm.2020.v05i12.008
17. Shinde SU, Gidde ND, Shinde PP, Kadam AB. An overview of nanoparticles: Current scenario. Research Journal of Pharmaceutical Dosage Forms and Technology. 2021;239–46. doi:10.52711/0975-4377.2021.00040
18. Amjad S, Serajuddin M. Nanoparticle Drug Delivery: An advanced approach for highly competent and multifunctional therapeutic treatment. Modelingand Control of Drug Delivery Systems. 2021;183–93. doi:10.1016/b978-0-12-821185-4.00008-7
19. Soni A, Gautam Y, Kumar I, Kumari C, Devi M, Yamini Y. Silver nanoparticle in Pharmaceuticals as Advanced Drug Delivery System. International Journal of Pharmaceutical Sciences Review and Research. 2023;79(2). doi:10.47583/ijpsrr.2023.v79i02.036
20. Maher R, Moreno-Borrallo A, Jindal D, Mai BT, Ruiz-Hernandez E, Harkin A. Intranasal polymeric and lipid-based nanocarriers for CNS drug delivery. Pharmaceutics. 2023;15(3):746. doi:10.3390/pharmaceutics15030746
21. Jiang X, Abedi K, Shi J. Polymeric nanoparticles for RNA delivery. Encyclopedia of Nanomaterials. 2023;555–73. doi:10.1016/b978-0-12-822425-0.00017-8
22. Sahle FF. Polymeric nanoparticles-based drug and gene delivery to macrophages. Macrophage Targeted Delivery Systems. 2022;145–67. doi:10.1007/978-3-030-84164-5_7
23. UtkarshDristant, Koel Mukherjee, SumitSaha, DipakMaity. Author response for “an overview of polymeric nanoparticles-based drug delivery system in cancer treatment.” 2022; doi:10.1177/15330338231152083/v2/response1
24. Müller RH, Runge SA. Solid lipid nanoparticles (SLN®) for Controlled Drug Delivery. Submicron Emulsions in Drug Targeting and Delivery. 2019;219–34. doi:10.1201/9780367810528-9
25. Gorzkiewicz M, Marcinkowska M, Studzian M, Karwaciak I, Pulaski L, Klajnert-Maculewicz B. Mesalazine–Pamam nanoparticles for transporter-independent intracellular drug delivery: Cellular uptake and anti-inflammatory activity. International Journal of Nanomedicine. 2023;Volume 18:2109–26. doi:10.2147/ijn.s390763

26. Eftekhari A, Kryschi C, Pamies D, Gulec S, Ahmadian E, Janas D, et al. Natural and synthetic nanovectors for cancer therapy. Nanotheranostics. 2023;7(3):236–57. doi:10.7150/ntno.77564
27. Gorzkiewicz M, Marcinkowska M, Studzian M, Karwaciak I, Pulaski L, Klajnert-Maculewicz B. Mesalazine–Pamam nanoparticles for transporter-independent intracellular drug delivery: Cellular uptake and anti-inflammatory activity. International Journal of Nanomedicine. 2023;Volume 18:2109–26. doi:10.2147/ijn.s390763
28. Farhaj S, Conway BR, Ghori MU. Nanofibres in Drug Delivery Applications. Fibers. 2023;11(2):21. doi:10.3390/fib11020021
29. Manzoor AA, Lindner LH, Landon CD, Park J-Y, Simnick AJ, Dreher MR, et al. Supplementary materials and methods from overcoming limitations in nanoparticle drug delivery: Triggered, intravascular release to improve drug penetration into tumors. 2023; doi:10.1158/0008-5472.22393964.v1
30. Zhu Y. Application of nanomaterials for drug delivery. Theoretical and Natural Science. 2023;3(1):521–8. doi:10.54254/2753-8818/3/20220348
31. SulaimanKhil NH, Sharma S, Sharma PK, Alam A. Several applications of solid lipid nanoparticles in drug delivery. Current Molecular Medicine. 2023;23. doi:10.2174/1566524023666230720110351
32. Chen D, Liu X, Lu X, Tian J. Nanoparticle drug delivery systems for synergistic delivery of tumor therapy. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1111991
33. Shakeel F. Editorial: Nanomedicine-based drug delivery systems: Recent developments and future prospects. Molecules. 2023;28(10):4138. doi:10.3390/molecules28104138
34. Almeida H, Silva AC. Nanoparticles in Ocular Drug Delivery Systems. Pharmaceutics. 2023;15(6):1675. doi:10.3390/pharmaceutics15061675
35. AjmalDrG. Implantable Drug Delivery Systems. Novel Drug Delivery System. 2022; doi:10.52458/9789391842871.2022.eb.grf.asu.ch.17
36. Pacheco C, Baião A, Ding T, Cui W, Sarmento B. Recent advances in long-acting drug delivery systems for Anticancer Drug. Advanced Drug Delivery Reviews. 2023;194:114724. doi:10.1016/j.addr.2023.114724
37. Mäder K. Characterization methodologies for long-acting and implantable drug delivery systems. Long-Acting Drug Delivery Systems. 2022;319–45. doi:10.1016/b978-0-12-821749-8.00001-x
38. Picco CJ, McKenna PE, Donnelly RF, Larrañeta E. Formulation of an implantable device from mini tablets-in-PCL cylinders for sustained delivery of a hydrophobic drug. 2022 APS Special Issue. 2022;7(2). doi:10.5920/bjpharm.1153
39. Li L, Lee C, Cruz D, Krovi S, Hudgens M, Cottrell M, et al. Reservoir-style polymeric drug delivery systems: Empirical and predictive models for implant design. Pharmaceuticals. 2022;15(10):1226. doi:10.3390/ph15101226
40. Zhao X, Deng M, Wang J, Liu B, Dong Y, Li Z. Miniaturized neural implants for localized and controllable drug delivery in the brain. Journal of Materials Chemistry B. 2023;11(27):6249–64. doi:10.1039/d3tb00728f
41. Singh M, Gill AS, Deol PK, Agrawal A, Sidhu SS. Drug Eluting titanium implants for localised drug delivery. Journal of Materials Research. 2022;37(16):2491–511. doi:10.1557/s43578-022-00609-y

42. Chavda VP, Jogi G, Paiva-Santos AC, Kaushik A. Biodegradable and removable implants for controlled drug delivery and release application. Expert Opinion on Drug Delivery. 2022;19(10):1177–81. doi:10.1080/17425247.2022.2110065
43. Gulati K. Electrochemically nano-engineered titanium implants towards local drug delivery applications. Advanced Porous Biomaterials for Drug Delivery Applications. 2022;281–310. doi:10.1201/9781003217114-13
44. Yang Y, Wu H, Fu Q, Xie X, Song Y, Xu M, et al. 3D-printed polycaprolactone-chitosan based drug delivery implants for personalized administration. Materials & Design. 2022;214:110394. doi:10.1016/j.matdes.2022.110394
45. Shakeel F. Editorial: Nanomedicine-based drug delivery systems: Recent developments and future prospects. Molecules. 2023;28(10):4138. doi:10.3390/molecules28104138
46. Nsairat H, Alshaer W, Odeh F, Esawi E, Khater D, Bawab AA, et al. Recent advances in using liposomes for delivery of nucleic acid-based therapeutics. OpenNano. 2023;11:100132. doi:10.1016/j.onano.2023.100132
47. Duong V-A, Nguyen T-T-L, Maeng H-J. Recent advances in intranasal liposomes for drug, gene, and vaccine delivery. Pharmaceutics. 2023;15(1):207. doi:10.3390/pharmaceutics15010207
48. Mundargi RC, Taneja N, Hadia JJ, Khopade AJ. Liposomes as targeted drug-delivery systems. Targeted Drug Delivery. 2022;69–125. doi:10.1002/9783527827855.ch4
49. Amreen S, Shahidulla SM, Sultana A, Fatima N. Implantable drug delivery system: An innovative approach. Journal of Drug Delivery and Therapeutics. 2023;13(5):98–105. doi:10.22270/jddt.v13i5.6069
50. Fulzele S, Bavaskar SR, Gayakwad BP, Sawale J, Yadav R, Gauttam V. An overview on implantable drug delivery system. Journal of Pharmaceutical Research International. 2022;1–13. doi:10.9734/jpri/2022/v34i25a35942
51. Yamayoshi A. Marerial symbiosis for drug delivery system. Drug Delivery System. 2022;37(2):99–99. doi:10.2745/dds.37.99
52. Major I, Lastakchi S, Dalton M, McConville C. Implantable Drug Delivery Systems. Engineering Drug Delivery Systems. 2020;111–46. doi:10.1016/b978-0-08-102548-2.00005-6
53. Omata D. Development of drug delivery system using lipid-based Microbubble and ultrasound. Drug Delivery System. 2019;34(2):132–3. doi:10.2745/dds.34.132
54. Zhao X, Deng M, Wang J, Liu B, Dong Y, Li Z. Miniaturized neural implants for localized and controllable drug delivery in the brain. Journal of Materials Chemistry B. 2023;11(27):6249–64. doi:10.1039/d3tb00728f
55. Singh M, Gill AS, Deol PK, Agrawal A, Sidhu SS. Drug Eluting titanium implants for localised drug delivery. Journal of Materials Research. 2022;37(16):2491–511. doi:10.1557/s43578-022-00609-y
56. Chavda VP, Jogi G, Paiva-Santos AC, Kaushik A. Biodegradable and removable implants for controlled drug delivery and release application. Expert Opinion on Drug Delivery. 2022;19(10):1177–81. doi:10.1080/17425247.2022.2110065
57. Yang Y, Wu H, Fu Q, Xie X, Song Y, Xu M, et al. 3D-printed polycaprolactone-chitosan based drug delivery implants for personalized administration. Materials & Design. 2022;214:110394. doi:10.1016/j.matdes.2022.110394

58. Amreen S, Shahidulla SM, Sultana A, Fatima N. Implantable drug delivery system: An innovative approach. Journal of Drug Delivery and Therapeutics. 2023;13(5):98–105. doi:10.22270/jddt.v13i5.6069
59. Li L, Qi Z. Recent advances in Cell-mediated drug delivery systems for nanomedicine and imaging. Fundamentals of Drug Delivery. 2021;263–84. doi:10.1002/9781119769644.ch10
60. Fulzele S, Bavaskar SR, Gayakwad BP, Sawale J, Yadav R, Gauttam V. An overview on implantable drug delivery system. Journal of Pharmaceutical Research International. 2022;1–13. doi:10.9734/jpri/2022/v34i25a35942
61. Vorrius B, Qiao Z, Ge J, Chen Q. Smart strategies to overcome drug delivery challenges in the musculoskeletal system. Pharmaceuticals. 2023;16(7):967. doi:10.3390/ph16070967
62. Adepu S, Ramakrishna S. Controlled Drug Delivery Systems: Current status and Future Directions. Molecules. 2021;26(19):5905. doi:10.3390/molecules26195905
63. Amreen S, Shahidulla SM, Sultana A, Fatima N. Implantable drug delivery system: An innovative approach. Journal of Drug Delivery and Therapeutics. 2023;13(5):98–105. doi:10.22270/jddt.v13i5.6069
64. Dhoundiyal S, Alam MA. Advances in pharmacokinetic modelling and computational approachesfor nanoparticles in Drug Delivery Systems. Recent Advances in Drug Delivery and Formulation. 2023;17. doi:10.2174/2667387817666230907093403
65. Fulzele S, Bavaskar SR, Gayakwad BP, Sawale J, Yadav R, Gauttam V. An overview on implantable drug delivery system. Journal of Pharmaceutical Research International. 2022;1–13. doi:10.9734/jpri/2022/v34i25a35942
66. Shukla MK, Tiwari H, Verma R, Dong W-L, Azizov S, Kumar B, et al. Role and recent advancements of ionic liquids in drug delivery systems. Pharmaceutics. 2023;15(2):702. doi:10.3390/pharmaceutics15020702
67. Barrera-Martínez CL, Guerrero-Hernández LA, Sánchez-Orozco JL, Cortez-Mazatan GY, Meléndez-Ortiz HI, Peralta-Rodríguez RD. Recent advancements in superabsorbent polymers for drug delivery. Properties and Applications of Superabsorbent Polymers. 2023;119–56. doi:10.1007/978-981-99-1102-8_6
68. Moghimipour E, Handali S. Targeted nano-drug delivery system to colon cancer. Smart Drug Delivery. 2022; doi:10.5772/intechopen.100059
69. Tewabe A, Abate A, Tamrie M, Seyfu A, AbdelaSiraj E. Targeted drug delivery — from Magic Bullet to Nanomedicine: Principles, challenges, and future perspectives. Journal of Multidisciplinary Healthcare. 2021;Volume 14:1711–24. doi:10.2147/jmdh.s313968
70. Magar Ganesh, PawarPriti, Kakade Swati, PawarSakshi. Review on targeted drug delivery system and its carriers as drug targeted to a specific organ. International Journal For Multidisciplinary Research. 2023;5(2).doi:10.36948/ijfmr.2023.v05i02.1973
71. Varshi R, Jain V, Pal P. A review on advanced approaches and polymers used in gastroretentive drug delivery systems. Journal of Drug Delivery and Therapeutics. 2022;12(4):181–5. doi:10.22270/jddt.v12i4.5422
72. Doshi KA. Basics of Targeted Drug Delivery. Targeted Drug Delivery. 2022;1–19. doi:10.1002/9783527827855.ch1
73. Azizi M, Kokabi H, Dianat-Moghadam H, Mehrmohammadi M. Passive targeting.

Targeted Cancer Imaging. 2022;37–47. doi:10.1016/b978-0-12-824513-2.00001-2
74. Vyas D, Patel M, Wairkar S. Strategies for active tumor targeting-an update. European Journal of Pharmacology. 2022;915:174512. doi:10.1016/j.ejphar.2021.174512
75. Hagimori M, Fuchigami Y, Kawakami S. Peptide-based cancer-targeted DDS and molecular imaging. CHEMICAL & PHARMACEUTICAL BULLETIN. 2017;65(7):618–24. doi:10.1248/cpb.c17-00098
76. Jonker M, King A, Krupp J, Rossow C, Sperotto A, Dainotti A. Millions of targets under attack. Proceedings of the 2017 Internet Measurement Conference. 2017; doi:10.1145/3131365.3131383
77. Zhao Y, Dzamko N. Recent developments in LRRK2-targeted therapy for parkinson's disease. Drugs. 2019;79(10):1037–51. doi:10.1007/s40265-019-01139-4
78. Salahuddin MA, Faizul Bari Md, Alameddine HA, Pourahmadi V, Boutaba R. Time-based anomaly detection using autoencoder. 2020 16th International Conference on Network and Service Management (CNSM). 2020; doi:10.23919/cnsm50824.2020.9269112
79. Bowtle WJ. Recent developments in oral multiphase and targeted release products. Pharmaceutical Science & Technology Today. 1999;2(1):32–6. doi:10.1016/s1461-5347(98)00107-2
80. 3 tensor products, Mackey formulas and Clifford Theory. Characters of Groups and Lattices over Orders. 2022;93–138. doi:10.1515/9783110702446-003
81. Pacheco C, Baião A, Ding T, Cui W, Sarmento B. Recent advances in long-acting drug delivery systems for Anticancer Drug. Advanced Drug Delivery Reviews. 2023;194:114724. doi:10.1016/j.addr.2023.114724
82. Alkufi H, Salman A, Taher S. Principles and advantages of New Drug Delivery Technologie. Journal of Complementary Medicine Research. 2023;14(3):6. doi:10.5455/jcmr.2023.14.03.02
83. Shaikh MS, Donnan R, Dubrovka R. Externally triggered drug delivery techniques using micro and nanoparticles. IEEE Journal of Electromagnetics, RF and Microwaves in Medicine and Biology. 2022;6(3):380–90. doi:10.1109/jerm.2022.3149685

HOW TO CITE: Varshini Y, Satish S, Revolutionizing Therapeutics: A Comprehensive Review on Clinical Approach Innovations in Drug Delivery Systems, Int. J. in Pharm. Sci., 2023, Vol 1, Issue 12, 604-616. https://doi.org/ 10.5281/zenodo.10423901